Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
HEДокторантска мрежа2023–2026

InnoCAR-T · Innovative design and implementation of next-generation Point-of-Care CAR-T

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2023-01-01 → 2026-12-31
Финансиране от ЕС
2 618 856 €
Участници
10
Схема
HORIZON-TMA-MSCA-DN

Линиите свързват координатора с партньорите.

Накратко на български

CAR-T терапиите за лечение на рак на кръвта се разработват за производство директно в болницата, вместо в централизирани заводи. Това ще намали разходите и времето за чакане, като помогне на повече пациенти да получат терапията навреме.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Innovative design and implementation of next-generation Point-of-Care CAR-T

Chimeric Antigen Receptor (CAR) T-cells (CAR-Ts) have emerged as a key breakthrough in the treatment of B-cell malignancies, with long term remission and cure in previously end-stage patients. These unprecedented clinical responses have clearly transformed the clinical landscape, with several commercial CAR-T products being available as standard-of-care in EU countries. However, the current commercial production paradigm by pharmaceutical companies poses significant challenges to rapid implementation. Specifically, products have long lead times, thereby, precluding severely ill patients from eligibility for this life-saving therapy. Further, centralized production poses challenges to rapid innovation and has significant environmental impact. Moreover, such centralized production of commercial CAR-T products has prohibitively high costs that strain the healthcare systems in Europe, even in the currently limited indication areas for which it is approved. Indeed, some countries do not include CAR-Ts in their public standard-of-care. Therefore, efforts currently focus on development of academic point-of-care (PoC) production as alternative, which is also the primary focus of InnoCAR-T. Furthermore, even for the successful story of B cell lymphoma long-term clinical responses are restricted to ~50% of patients, whereas for most other types of cancers clear CAR-T breakthroughs are still lacking. This is due to additional challenges that need to be overcome for effective CAR-T therapy, including tumour micro-environmental immunosuppression that results in the shut-down of CAR-T in the tumour lesion. InnoCAR-T’s science objective is to use breakthrough science to develop next-generation academic CAR-T products that aim to address these bottlenecks and deliver curative CAR-T-based tumour immunity with optimal and affordable care. Specifically, we will 1. develop flexible, scalable and rapid CAR-T manufacturing capacity for academia and 2. develop various immunomodulatory therapeutic approaches for the design of next-generation CAR-T formulations to overcome immunosuppression. With these advances, InnoCAR-T aims to drive the implementation of PoC CAR-T therapy in Europe.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

InnoCAR-T is a Doctoral Network designed to provide training and carry out breakthrough research on the high impact field of Chimeric Antigen Receptor (CAR) T cell immunotherapy in a carefully integrated academic and inter-sectoral programme. We aim to develop next-generation CAR-T therapy and deliver a set of young researchers uniquely qualified for a career in academia and/or industry.CAR-T cell therapy represents a revolutionary advance in oncology, particularly for B cell lymphoma patients. However, long-term response is still restricted to ~50% of patients, with resistance being even more prominent in other cancers. Thus, additional innovations to overcome resistance are needed to improve CAR-T responses. Unfortunately, the currently centralized production of CAR-T hampers rapid innovation and associates with prohibitive costs, long vein-to-vein time, and poor carbon footprint due to inter-continental delivery.InnoCAR-T aims touse innovative academic and industrial concepts to address these issues by 1. developing innovative manufacturing solutions for CAR-T production at local academic hospitals and 2. developing the next-generation of more effective CAR-Ts.At the core of InnoCAR-T is its training objective to offer a cutting-edge multidisciplinary training programme. Herewith, outstanding young scientists can generate breakthrough ideas and assume leading positions in academia and industry. The training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, CAR engineering, gene-editing), physical sciences to mechanical engineering.Industrial partners are central to the programme and provide pivotal expertise on how to translate scientific discoveries into commercial reality. Inter-sectoral partners will host Doctoral Candidates, provide key secondments and network-wide training events. Further, InnoCAR-T will foster long-term multi-disciplinary research and bilateral co-operations between academia and industry.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз